Astellas's Q1 sales and profit slide as generics hit hard
This article was originally published in Scrip
Executive Summary
Generic competition in the US for Astellas's lead products, Prograf and Flomax/Harnal, continued to cut into the company's sales and profits during the first quarter of the new fiscal year.